AliveDx Receives Three IVDR CE Marks For Its Multiplexed Autoimmune Diagnostics Solution
Portfolio Pulse from Benzinga Newsdesk
AliveDx has received three IVDR CE Marks for its MosaiQ solution, a multiplexed autoimmune diagnostics solution. The marks were awarded for the MosaiQ Centromere Protein B (CENP-B) microarray, the MosaiQ AiPlex CTD multiplexed microarray immunoassays, and the MosaiQ AiPlex CTD Quality Controls. The company plans to launch its autoimmune testing portfolio in the European Union and other CE Mark recognizing geographies, aiming to provide improved workflow and faster diagnosis and treatment of patients with autoimmune diseases.
October 30, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Although QTNTQ is not directly mentioned in the article, the news about AliveDx's MosaiQ solution receiving three IVDR CE Marks could potentially impact QTNTQ if there is a business relationship between the two companies.
The article does not mention QTNTQ directly, and there is no information provided about a business relationship between AliveDx and QTNTQ. Therefore, the potential impact on QTNTQ is uncertain.
CONFIDENCE 50
IMPORTANCE 0
RELEVANCE 0